SCHEMBL4579742

SCHEMBL4579742

CC(=O)Oc1ccc(C(=O)Nc2cc(C3=CC(=O)CC3)ccc2NC(=O)OC(C)(C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.46
MEN1 O00255 5/20 0.46
LMNA P02545 3/20 0.43
MAPT P10636 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
F10 P00742 1/20 0.41
HPGD P15428 1/20 0.39
HDAC1 Q13547 1/20 0.38
PKM P14618 2/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
POLB P06746 1/20 0.38
HTT P42858 1/20 0.38
RECQL P46063 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CYP17A1 P05093 1/20 0.38
NR1I2 O75469 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4580317 0.82 HDAC2 (0.52) KMT2AMEN1LMNAMAPTHDAC1
SCHEMBL5767872 0.79 HDAC1 (0.56) KMT2AMEN1NPSR1KDM4EALDH1A1
SCHEMBL8229079 0.76 AAK1 (0.42) HDAC1CYP17A1
SCHEMBL4579745 0.73 GFER (0.35) KMT2AMEN1LMNAMAPTALDH1A1
SCHEMBL8223596 0.73 ABCB1 (0.42) KMT2AMEN1ALDH1A1
SCHEMBL14156007 0.72 F10 (0.55) KMT2AMEN1MAPTKDM4EALDH1A1
SCHEMBL6814994 0.71 NAMPT (0.60) KMT2AMEN1LMNAMAPTNPSR1
SCHEMBL12933541 0.71 MEN1 (0.78) KMT2AMEN1MAPTNPSR1KDM4E
SCHEMBL4580342 0.71 F10 (0.53) KMT2AMEN1MAPTKDM4EALDH1A1
SCHEMBL4579767 0.70 MEN1 (0.52) KMT2AMEN1NPSR1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2007720-B1 BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2013-12-25 EP disclosed
US-8598168-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2013-12-03 US disclosed
US-20080132503-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-06-05 US disclosed
US-20080132503-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-06-05 US disclosed
WO-2007118137-A1 BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132503-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 KMT2A 52/4885MEN1 2635/4885LMNA 1922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.